Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Haemorrhage/shock
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 10
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
A Randomized, 52 Week, Double-blind, Multicentre, Parallel, Placebo-controlled Phase 2b Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Investigating the Efficacy and Safety of GB0139, an Inhaled Galectin-3 Inhibitor
Idiopathic Pulmonary Fibrosis (IPF)
Enrolment: 172 · Results not recorded
Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin-3 Inhibitor (GB1211) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Metastatic Melanoma · Head and Neck Squamous Cell Carcinoma
Enrolment: 92 · Results not recorded
GULLIVER-2 - A Single (Open-label) and Repeat Dose Trial to Assess the Safety, Tolerability and Pharmacokinetics of GB1211 in Participants With Hepatic Impairment (Child Pugh B & C)
Hepatic Impairment
Enrolment: 54 · Results not recorded
An Open Label Study Followed by a Randomised, Double-blind, Placebo-controlled, Parallel Group and an Extension Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Enrolment: 88 · Results not recorded
GULLIVER-1 - A Randomised, Double-Blind, Placebo Controlled, Phase Ib, 12-week Study to Evaluate GB1211 in Participants With Suspected or Confirmed NASH and Liver Fibrosis
Non-alcoholic Steatohepatitis (NASH)
Enrolment: 0 · Results not recorded
DEFINE - Evaluating Therapies for COVID-19 (includes TD139)
COVID-19
Enrolment: 71 · Results not recorded
Phase I/II Study of Peptide Vaccination Associated With GM-CT-01, a Galactomannan Oligomer That Inhibits Galectin-3, in Patients With Advanced Metastatic Melanoma
Metastatic Melanoma
Enrolment: 6 · Results not recorded
A Placebo-controlled RCT in Healthy Volunteers Investigating the Safety, Tolerability and PK of TD139, a Galectin-3 Inhibitor, Followed by an Expansion Cohort Treating Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Enrolment: 60 · Results not recorded
Phase I Trial of GB1211 (Selvigaltin), an Oral Galectin-3 Inhibitor, Combined With Standard of Care Treatment in Relapsed/Refractory Multiple Myeloma
Recurrent Multiple Myeloma · Refractory Multiple Myeloma
Enrolment: 0 · Results not recorded
Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
Metastatic Melanoma
Enrolment: 8 · Results not recorded
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseHaemorrhage/shockUnspecified
Model: Subarachnoid haemorrhage produced by endovascular perforation of the top of the internal carotid artery with a 4-0 monofilament, with assessment of early brain injury
Administration of a galectin-3 inhibitor significantly reduced brain oedema and improved neurological score at 24 h in mice with experimental subarachnoid haemorrhage.
Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.
